Skip to main content
NCD 190.23 · version 2 · Laboratory NCD

NCD 190.23: Lipid Testing

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database NCDs: API snapshot September 27, 2026 (effective September 20, 2026); Lab NCD code lists: October 2026 (effective October 1, 2026). Next CMS release: weekly, every Thursday for the Medicare Coverage Database NCDs; January 1, 2027 (quarterly update) for the Lab NCD code lists.

Medicare Coverage Database NCDs: the loaded version is API snapshot September 27, 2026, and the CMS schedule called for a newer one from October 1, 2026. Verify figures against the current CMS publication until this reference is rebuilt; pages built on it are withdrawn from search indexing until then.

Key facts for NCD 190.23

Benefit category
Diagnostic Laboratory Tests
Effective date
01/01/2005
Implemented 03/11/2005
Transmittal
Transmittal 28
Versions published
2
Manual section
190
Pathology and Laboratory, NCD Manual (Pub. 100-03) chapter 1 part 3
Lab edit list
3,353 covered ICD-10
466 non-covered

TL;DR

NCD 190.23 sets Medicare's national policy for lipid testing under the benefit category "Diagnostic Laboratory Tests", effective 01/01/2005 and implemented 03/11/2005. The medical community recognizes lipid testing as appropriate for evaluating atherosclerotic cardiovascular disease. Conditions in which lipid testing may be indicated include: As a laboratory NCD it carries a national ICD-10 edit list: 3,353 diagnosis codes support medical necessity and 466 are denied, applied automatically by every Medicare contractor to 8 procedure codes.

Item or service described

Lipoproteins are a class of heterogeneous particles of varying sizes and densities containing lipid and protein. These lipoproteins include cholesterol esters and free cholesterol, triglycerides, phospholipids and A, C, and E apoproteins. Total cholesterol comprises all the cholesterol found in various lipoproteins.

Factors that affect blood cholesterol levels include age, sex, body weight, diet, alcohol and tobacco use, exercise, genetic factors, family history, medications, menopausal status, the use of hormone replacement therapy, and chronic disorders such as hypothyroidism, obstructive liver disease, pancreatic disease (including diabetes), and kidney disease.

In many individuals, an elevated blood cholesterol level constitutes an increased risk of developing coronary artery disease. Blood levels of total cholesterol and various fractions of cholesterol, especially low density lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C), are useful in assessing and monitoring treatment for that risk in patients with cardiovascular and related diseases. Blood levels of the above cholesterol components including triglyceride have been separated into desirable, borderline and high risk categories by the National Heart, Lung and Blood Institute in their report in 1993. These categories form a useful basis for evaluation and treatment of patients with hyperlipidemia. Therapy to reduce these risk parameters includes diet, exercise and medication, and fat weight loss, which is particularly powerful when combined with diet and exercise.

Indications and limitations of coverage

Indications

The medical community recognizes lipid testing as appropriate for evaluating atherosclerotic cardiovascular disease. Conditions in which lipid testing may be indicated include:

• Assessment of patients with atherosclerotic cardiovascular disease.

• Evaluation of primary dyslipidemia.

• Any form of atherosclerotic disease, or any disease leading to the formation of atherosclerotic disease.

• Diagnostic evaluation of diseases associated with altered lipid metabolism, such as: nephrotic syndrome, pancreatitis, hepatic disease, and hypo and hyperthyroidism.

• Secondary dyslipidemia, including diabetes mellitus, disorders of gastrointestinal absorption, chronic renal failure.

• Signs or symptoms of dyslipidemias, such as skin lesions.

• As follow-up to the initial screen for coronary heart disease (total cholesterol + HDL cholesterol) when total cholesterol is determined to be high (>240 mg/dL), or borderline-high (200-240 mg/dL) plus two or more coronary heart disease risk factors, or an HDL cholesterol,

To monitor the progress of patients on anti-lipid dietary management and pharmacologic therapy for the treatment of elevated blood lipid disorders, total cholesterol, HDL cholesterol and LDL cholesterol may be used. Triglycerides may be obtained if this lipid fraction is also elevated or if the patient is put on drugs (for example, thiazide diuretics, beta blockers, estrogens, glucocorticoids, and tamoxifen) which may raise the triglyceride level.

When monitoring long term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it may be reasonable to perform the lipid panel annually. A lipid panel at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.

Any one component of the panel or a measured LDL may be reasonable and necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.

Electrophoretic or other quantitation of lipoproteins may be indicated if the patient has a primary disorder of lipoid metabolism.

Effective January 1, 2005, the Medicare law expanded coverage to cardiovascular screening services. Several of the procedures included in this NCD may be covered for screening purposes subject to specified frequencies. See 42 CFR 410.17 and section 100, chapter 18, of the Claims Processing Manual , for a full description of this benefit.

Limitations

Lipid panel and hepatic panel testing may be used for patients with severe psoriasis which has not responded to conventional therapy and for which the retinoid etretinate has been prescribed and who have developed hyperlipidemia or hepatic toxicity. Specific examples include erythrodermia and generalized pustular type and psoriasis associated with arthritis.

Routine screening and prophylactic testing for lipid disorder are not covered by Medicare. While lipid screening may be medically appropriate, Medicare by statute does not pay for it. Lipid testing in asymptomatic individuals is considered to be screening regardless of the presence of other risk factors such as family history, tobacco use, etc.

Once a diagnosis is established, one or several specific tests are usually adequate for monitoring the course of the disease. Less specific diagnoses (for example, other chest pain) alone do not support medical necessity of these tests.

When monitoring long term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it is reasonable to perform the lipid panel annually. A lipid panel at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.

Any one component of the panel or a measured LDL may be medically necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.

If no dietary or pharmacological therapy is advised, monitoring is not necessary.

When evaluating non-specific chronic abnormalities of the liver (for example, elevations of transaminase, alkaline phosphatase, abnormal imaging studies, etc.), a lipid panel would generally not be indicated more than twice per year.

Note: Scroll down for links to the quarterly Covered Code Lists (including narrative).

Text reproduced from the CMS Medicare Coverage Database record for NCD 190.23 version 2. View the original on cms.gov.

Laboratory NCD code lists (October 2026)

Medicare contractors apply this NCD through a national edit: the procedure codes below are paid only when the claim carries a covered diagnosis. The October 2026 list holds 3,353 covered and 466 non-covered ICD-10-CM codes; any code not on the list does not support medical necessity.

8 procedure codes are edited against this NCD's diagnosis list. CPT codes are shown as numbers only; descriptors are licensed by the AMA.

Procedure codes subject to NCD 190.23
CodeCode set
80061CPT (descriptor licensed by AMA)
82465CPT (descriptor licensed by AMA)
83700CPT (descriptor licensed by AMA)
83701CPT (descriptor licensed by AMA)
83704CPT (descriptor licensed by AMA)
83718CPT (descriptor licensed by AMA)
83721CPT (descriptor licensed by AMA)
84478CPT (descriptor licensed by AMA)

What Medicare pays for these tests: 8 of the 8 codes carry a national payment amount on the October 2026 Clinical Laboratory Fee Schedule, from $4.35 to $34.19, with no deductible or coinsurance. QW marks the CLIA-waived variant of a test.

Clinical Laboratory Fee Schedule amounts for the codes NCD 190.23 edits, October 2026
CodeCLFS amountWith QWPricing
80061$13.39$13.39national payment amount
82465$4.35$4.35national payment amount
83700$11.26—national payment amount
83701$33.86—national payment amount
83704$34.19—national payment amount
83718$8.19$8.19national payment amount
83721$10.50$10.50national payment amount
84478$5.74$5.74national payment amount
Source: CMS Clinical Laboratory Fee Schedule 26CLABQ4. Every code range and the October changes are on the Clinical Laboratory Fee Schedule page.

The first 40 of 3,353 covered diagnosis codes, with FY2027 ICD-10-CM descriptions. A claim with any covered code on the line supports medical necessity under the national edit.

Covered ICD-10-CM codes for NCD 190.23 (sample)
ICD-10-CMDescriptionEffective
B25.2Cytomegaloviral pancreatitis2015-10-01
B52.0Plasmodium malariae malaria with nephropathy2015-10-01
E00.0Congenital iodine-deficiency syndrome, neurological type2015-10-01
E00.1Congenital iodine-deficiency syndrome, myxedematous type2015-10-01
E00.2Congenital iodine-deficiency syndrome, mixed type2015-10-01
E00.9Congenital iodine-deficiency syndrome, unspecified2015-10-01
E01.8Other iodine-deficiency related thyroid disorders and allied conditions2015-10-01
E02Subclinical iodine-deficiency hypothyroidism2015-10-01
E03.0Congenital hypothyroidism with diffuse goiter2015-10-01
E03.1Congenital hypothyroidism without goiter2015-10-01
E03.2Hypothyroidism due to medicaments and other exogenous substances2015-10-01
E03.3Postinfectious hypothyroidism2015-10-01
E03.4Atrophy of thyroid (acquired)2016-10-01
E03.8Other specified hypothyroidism2015-10-01
E03.9Hypothyroidism, unspecified2015-10-01
E05.00Thyrotoxicosis with diffuse goiter without thyrotoxic crisis or storm2015-10-01
E05.01Thyrotoxicosis with diffuse goiter with thyrotoxic crisis or storm2015-10-01
E05.10Thyrotoxicosis with toxic single thyroid nodule without thyrotoxic crisis or storm2015-10-01
E05.11Thyrotoxicosis with toxic single thyroid nodule with thyrotoxic crisis or storm2015-10-01
E05.20Thyrotoxicosis with toxic multinodular goiter without thyrotoxic crisis or storm2015-10-01
E05.21Thyrotoxicosis with toxic multinodular goiter with thyrotoxic crisis or storm2015-10-01
E05.30Thyrotoxicosis from ectopic thyroid tissue without thyrotoxic crisis or storm2015-10-01
E05.31Thyrotoxicosis from ectopic thyroid tissue with thyrotoxic crisis or storm2015-10-01
E05.40Thyrotoxicosis factitia without thyrotoxic crisis or storm2015-10-01
E05.41Thyrotoxicosis factitia with thyrotoxic crisis or storm2015-10-01
E05.80Other thyrotoxicosis without thyrotoxic crisis or storm2015-10-01
E05.81Other thyrotoxicosis with thyrotoxic crisis or storm2015-10-01
E05.90Thyrotoxicosis, unspecified without thyrotoxic crisis or storm2015-10-01
E05.91Thyrotoxicosis, unspecified with thyrotoxic crisis or storm2015-10-01
E06.0Acute thyroiditis2015-10-01
E06.1Subacute thyroiditis2015-10-01
E06.2Chronic thyroiditis with transient thyrotoxicosis2015-10-01
E06.3Autoimmune thyroiditis2015-10-01
E06.4Drug-induced thyroiditis2015-10-01
E06.5Other chronic thyroiditis2015-10-01
E06.9Thyroiditis, unspecified2015-10-01
E08.00Diabetes mellitus due to underlying condition with hyperosmolarity without nonketotic hyperglycemic-hyperosmolar coma (NKHHC)2015-10-01
E08.01Diabetes mellitus due to underlying condition with hyperosmolarity with coma2015-10-01
E08.10Diabetes mellitus due to underlying condition with ketoacidosis without coma2015-10-01
E08.11Diabetes mellitus due to underlying condition with ketoacidosis with coma2015-10-01

466 diagnosis codes deny automatically under this NCD; the first 20 are shown.

Non-covered ICD-10-CM codes for NCD 190.23 (sample)
ICD-10-CMDescription
R99Ill-defined and unknown cause of mortality
Z00.00Encounter for general adult medical examination without abnormal findings
Z00.01Encounter for general adult medical examination with abnormal findings
Z00.110Health examination for newborn under 8 days old
Z00.111Health examination for newborn 8 to 28 days old
Z00.121Encounter for routine child health examination with abnormal findings
Z00.129Encounter for routine child health examination without abnormal findings
Z00.5Encounter for examination of potential donor of organ and tissue
Z00.6Encounter for examination for normal comparison and control in clinical research program
Z00.70Encounter for examination for period of delayed growth in childhood without abnormal findings
Z00.71Encounter for examination for period of delayed growth in childhood with abnormal findings
Z00.8Encounter for other general examination
Z02.0Encounter for examination for admission to educational institution
Z02.1Encounter for pre-employment examination
Z02.2Encounter for examination for admission to residential institution
Z02.3Encounter for examination for recruitment to armed forces
Z02.4Encounter for examination for driving license
Z02.5Encounter for examination for participation in sport
Z02.6Encounter for examination for insurance purposes
Z02.71Encounter for disability determination

Changed in October 2026

The October 2026 lab NCD release made no change to this NCD's ICD-10-CM list: no code was added, removed or given a new result against January 2026. The last change was in January 2026, when CMS added 5 codes.

Codes on this NCD's list by release: October 2025: 1,943 · January 2026: 1,948 · October 2026: 1,948. Every change across the 23 laboratory NCDs is in the lab NCD code-list change report.

Local policies that build on this NCD

5 active Local Coverage Determinations cite NCD 190.23 among their related national policies. An LCD may not conflict with the national determination; read it for the contractor's documentation and coding detail in that jurisdiction.

How MACs bill NCD 190.23

A National Coverage Determination states the policy; the Medicare Administrative Contractors publish the articles that turn it into claim edits. 4 current articles in the Medicare Coverage Database name NCD 190.23, 4 of them with a covered ICD-10-CM list, from 4 contractors. The lists can differ by contractor even though the NCD is national, because each MAC codes the policy for its own claims system; check the article of the contractor that processes the claim.

A56943: Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment

Billing and Coding, effective 2026-10-01 · Palmetto GBA (10111, 10112, 10211, 10212, 10311, 10312, 11201, 11202, 11301, 11302, 11401, 11402, 11501, 11502) · CMS record

180 covered ICD-10-CM codes; 11 procedure codes: 82172, 82610, 83090, 83695, 83698, 83700, 83701, 83704, 83719, 83721, 86141. Local policy: L36129 MolDX: Biomarkers in Cardiovascular Risk Assessment. Check a diagnosis for 82172.

First covered codes: E71.30 Disorder of fatty-acid metabolism, unspecified; E75.21 Fabry (-Anderson) disease; E75.22 Gaucher disease; E75.240 Niemann-Pick disease type A; E75.241 Niemann-Pick disease type B; E75.242 Niemann-Pick disease type C; …

A57037: Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment

Billing and Coding, effective 2026-10-01 · Noridian Healthcare Solutions, LLC (01111, 01112, 01182, 01211, 01212, 01311, 01312, 01911, 02101, 02102, 02201, 02202, 02301, 02302, 02401, 02402, 03101, 03102, 03201, 03202, 03301, 03302, 03401, 03402, 03501, 03502, 03601, 03602) · CMS record

180 covered ICD-10-CM codes; 11 procedure codes: 82172, 82610, 83090, 83695, 83698, 83700, 83701, 83704, 83719, 83721, 86141. Local policy: L36358 MolDX: Biomarkers in Cardiovascular Risk Assessment. Check a diagnosis for 82172.

First covered codes: E71.30 Disorder of fatty-acid metabolism, unspecified; E75.21 Fabry (-Anderson) disease; E75.22 Gaucher disease; E75.240 Niemann-Pick disease type A; E75.241 Niemann-Pick disease type B; E75.242 Niemann-Pick disease type C; …

A57386: Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment

Billing and Coding, effective 2026-10-01 · CGS Administrators, LLC (15101, 15102, 15201, 15202) · CMS record

181 covered ICD-10-CM codes; 11 procedure codes: 82172, 82610, 83090, 83695, 83698, 83700, 83701, 83704, 83719, 83721, 86141. Local policy: L36139 MolDX: Biomarkers in Cardiovascular Risk Assessment. Check a diagnosis for 82172.

First covered codes: E71.30 Disorder of fatty-acid metabolism, unspecified; E75.21 Fabry (-Anderson) disease; E75.22 Gaucher disease; E75.240 Niemann-Pick disease type A; E75.241 Niemann-Pick disease type B; E75.242 Niemann-Pick disease type C; …

A57559: Billing and Coding: MolDX: Biomarkers in Cardiovascular Risk Assessment

Billing and Coding, effective 2026-10-01 · Wisconsin Physicians Service Insurance Corporation (05101, 05102, 05201, 05202, 05301, 05302, 05401, 05402, 05901, 08101, 08102, 08201, 08202) · CMS record

180 covered ICD-10-CM codes; 12 procedure codes: 82172, 82610, 83090, 83695, 83698, 83700, 83701, 83704, 83719, 83721, 83880, 86141. Local policy: L36523 MolDX: Biomarkers in Cardiovascular Risk Assessment. Check a diagnosis for 82172.

First covered codes: E71.30 Disorder of fatty-acid metabolism, unspecified; E75.21 Fabry (-Anderson) disease; E75.22 Gaucher disease; E75.240 Niemann-Pick disease type A; E75.241 Niemann-Pick disease type B; E75.242 Niemann-Pick disease type C; …

Coverage analysis history

CMS opens a national coverage analysis (NCA) to create or reconsider an NCD; the analysis carries a CAG tracking number, the evidence review and the decision memo. The Medicare Coverage Database links one analysis to NCD 190.23, listed here in the order CMS opened them (by NCA record number). A reconsideration ("Recon") revisits an earlier decision; an analysis whose status is open is still in progress.

  1. CAG-00188N Lipid Testing (Clarification of ICD-9-CM Codes for Hypertension) (New, Closed)

Revision history

02/2005 - Added reference to screening benefits. Effective date 1/01/05. Implementation date 3/11/05. ( TN 28 ) (CR 3690)

07/2004 - Published NCD in NCD Manual without change to narrative contained in PM AB-02-110. Coding guidance published in Medicare Lab NCD Manual. Effective and Implementation dates NA. ( TN 17 ) (CR 2130)

07/2002 - Implemented NCD. Effective date 11/25/02. Implementation date 1/01/03. ( TN AB-02-110 ) (CR 2130)

How this NCD shows up on remittances

A service denied under a National Coverage Determination returns CARC 50 (not deemed medically necessary) with remark N386 (decision based on an NCD); a denial citing a local policy instead carries N115. Because NCDs bind nationally, the appeal path is documentation that the patient meets the indications above, not a contractor-policy argument.

For teams evaluating QuickIntell software

Evaluate a coverage-review workflow around NCD 190.23

Explore QuickAuth for requirement checks, documentation preparation and status tracking with staff oversight. Bring the policy-review steps your team repeats to a scoped evaluation, and confirm plan-specific requirements and supported actions. Use QuickRCM to evaluate the separate claim and denial workflow; a published NCD is not an authorization or payment guarantee.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — NCD 190.23

What does NCD 190.23 cover?

The medical community recognizes lipid testing as appropriate for evaluating atherosclerotic cardiovascular disease. Conditions in which lipid testing may be indicated include: The full indications and limitations are reproduced on this page from the CMS Medicare Coverage Database.

When did NCD 190.23 take effect?

The current version (2) is effective 01/01/2005, implemented 03/11/2005, published in transmittal 28. CMS lists 2 versions of this NCD.

Does a Local Coverage Determination override NCD 190.23?

No. A National Coverage Determination binds all Medicare Administrative Contractors; an LCD can only address services or circumstances the NCD leaves open. Claims denied under this NCD typically return CARC 50 with remark N386 (NCD) rather than N115 (LCD).

Which diagnosis codes are covered under NCD 190.23?

The October 2026 laboratory NCD edit list contains 3,353 ICD-10-CM codes that support lipid testing (for example B25.2 Cytomegaloviral pancreatitis; B52.0 Plasmodium malariae malaria with nephropathy; E00.0 Congenital iodine-deficiency syndrome, neurological type) and 466 codes that deny. The list applies to 80061, 82465, 83700, 83701, 83704, 83718 and others.

How often does the lab NCD code list for 190.23 change?

CMS updates the laboratory NCD edit module quarterly, with the October release carrying the annual ICD-10-CM code changes. Codes added or deleted mid-year appear in the quarterly change spreadsheets on the Lab NCDs page.

CMS guidance

Medicare Learning Network publications that CMS issues on this topic, cited by ICN and publication date:

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page reproduces the CMS National Coverage Determination text and, for laboratory NCDs, the CMS ICD-10 edit lists, as an operational reference. Coverage decisions depend on the full policy, the claim and the contractor; nothing here is legal, clinical or billing advice. CPT codes are shown as numbers only; CPT descriptors are copyright AMA.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.